4.7 Letter

Treasure or artifact: a decade of p63 research speaks for itself

Journal

CELL DEATH AND DIFFERENTIATION
Volume 17, Issue 1, Pages 180-183

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2009.157

Keywords

-

Funding

  1. NIAMS NIH HHS [K99 AR054696-02, K99 AR054696, R00 AR054696] Funding Source: Medline
  2. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K99AR054696, R00AR054696] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Dermatology

Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab

G. Pavia, L. Gargiulo, F. Spinelli, J. Avagliano, M. Valenti, R. G. Borroni, A. Costanzo, A. Narcisi

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Article Dermatology

Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study

Luigi Gargiulo, Giulia Pavia, Mario Valenti, Ana Lleo de Nalda, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi

Summary: This study assessed the safety of biologic drugs in patients with psoriasis and viral hepatitis without antiviral prophylaxis. The results showed that biologic therapies, including anti-IL-23 drugs, appeared to be safe in patients seropositive for HCV or HBV core antibody.

DERMATOLOGY AND THERAPY (2022)

Letter Dermatology

Monkeypox infection with perianal lesions, fever, and lymphadenopathy

Luciano Ibba, Luigi Gargiulo, Casana Maddalena, Francesco Sacrini, Alessandra Narcisi, Paola Morelli, Antonio Costanzo, Luca Livio Mancini

INTERNATIONAL JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)

Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, Luciano Ibba, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Francesca Sampogna, Massimo Travaglini, Piergiorgio Malagoli, Antonio Costanzo

Summary: This retrospective study assessed the effectiveness and safety of tildrakizumab in the real-life clinical practice for treating plaque psoriasis. The results showed that a significant proportion of patients achieved PASI 75, PASI 90, and PASI 100 at 52 weeks, with higher percentages achieving complete skin clearance. No significant safety concerns were observed, and no patients had to discontinue treatment due to adverse events.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Genetics & Heredity

Rare diseases of ectoderm: Translating discovery to therapy

John Timothy Wright, Becky M. Abbott, Maddison N. Salois, Jessica A. Gugger, Shirley P. Parraga, Amanda K. Swanson, Mary Fete, Maranke I. Koster

Summary: Heritable conditions known as ectodermal dysplasias are rare and can have significant impacts on morbidity, mortality, and quality of life. Diagnosing and caring for individuals with these conditions is challenging due to their rarity and diverse phenotypes. Researchers and clinicians gathered at a 2021 international conference to advance the diagnosis and treatment of ectodermal conditions, focusing on skin, hair, tooth, and eye phenotypes. Promising treatment strategies discussed included gene or protein replacement, gene editing, cell therapy, and identifying druggable targets. Barriers hindering the development of novel therapeutics were also addressed, such as lack of prevalence data, patient registries, and animal models. Overcoming these barriers is crucial for the development of new treatments for genetic disorders of the ectoderm.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2023)

Letter Dermatology

Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction

Giovanni Fiorillo, Francesco Toso, Andrea Cortese, Francesco Piscazzi, Alessandra Bressan, Stefania Bramanti, Sofia Manara, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study

Lars Iversen, Curdin Conrad, Liv Eidsmo, Antonio Costanzo, Joanna Narbutt, Andreas Pinter, Kulli Kingo, Raquel Rivera Diaz, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Annika Frueh, Piotr Jagiello

Summary: The purpose of this study was to compare the effectiveness of early intervention with secukinumab and traditional nb-UVB phototherapy in patients with new-onset moderate to severe plaque psoriasis. The results showed that secukinumab was more effective than nb-UVB, and early use of biologic treatment may be more effective in treating psoriasis.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice

Antonio Costanzo, Mar Llamas-Velasco, Gabriella Fabbrocini, Aldo Cuccia, Raquel Rivera-Diaz, Kristian Gaarn Du Jardin, Ismail Kasujee, Lluis Puig, Jose Manuel Carrascosa

Summary: The TRIBUTE study assessed the efficacy and impact on health-related quality of life of Tildrakizumab in moderate-to-severe psoriasis patients in conditions similar to clinical practice. After 24 weeks, a high proportion of patients achieved significant improvement in psoriasis signs and quality of life. Patient-reported outcomes showed improvements in sleep outcomes, work productivity, and treatment satisfaction. The safety profile was favorable.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Effects of TP63 mutations on keratinocyte adhesion and migration

Maddison N. Salois, Jessica A. Gugger, Saiphone Webb, Christina E. Sheldon, Shirley P. Parraga, G. Michael Lewitt, Dorothy K. Grange, Peter J. Koch, Maranke I. Koster

Summary: The aim of this study was to investigate the molecular mechanisms underlying skin erosions in AEC patients. iPSCs were generated from AEC patients and TP63 mutations were corrected. Downregulation of key components of hemidesmosomes and focal adhesions was observed in AEC iPSC-K. Reduced migration of AEC iPSC-K and abnormalities in skin tissues of AEC patients were also observed. Integration defects and downregulation of extracellular matrix adhesion receptors may contribute to the formation of skin erosions in AEC.

EXPERIMENTAL DERMATOLOGY (2023)

Letter Dermatology

Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study

L. Gargiulo, L. Ibba, F. Piscazzi, A. Alfano, R. Cascio Ingurgio, M. Valenti, A. Costanzo, A. Narcisi

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience

D. Orsini, P. Frascione, C. Assorgi, A. Pacifico, I. Sperduti, L. Gargiulo, L. Ibba, M. Valenti, A. Costanzo, A. Narcisi

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis

L. Gargiulo, L. Ibba, G. Fiorillo, M. Valenti, P. Sierzputowska, A. Costanzo, A. Narcisi

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case-series

F. Bellinato, P. Gisondi, A. Dattola, A. G. Richetta, A. Costanzo, M. Valenti, C. De Simone, A. V. Marzano, M. Zussino, E. Pezzolo, M. Nacca, G. Pellacani, G. Girolomoni

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Meeting Abstract Dermatology

Identifying predictors of high response levels in ixekizumab-treated patients with moderate-to-severe plaque psoriasis

Kristian Reich, Kilian Eyerich, Antonio Costanzo, Mark Lebwohl, Alyssa Garrelts, Daniel Saure, Christopher Schuster, Andrew Blauvelt, David Truong

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)

Meeting Abstract Dermatology

Updates on COVID-19 cases and SARS-CoV-2 vaccinations during tralokinumab treatment in moderate-to-severe atopic dermatitis from ECZTEND long-term extension trial

R. Langley, A. Pink, M. Worm, A. Costanzo, L. Gjerum, E. Jorgensen, J. Corriveau, S. Schneider, E. Guttman-Yassky, A. Blauvelt

BRITISH JOURNAL OF DERMATOLOGY (2022)

No Data Available